The global seborrheic dermatitis market accounted for USD 2.68 billion in 2023 and is expected to reach USD 8.48 billion by 2034 with a CAGR of 11.04% during the forecast period 2024-2034. The market will grow as a result of factors such as rising rates of seborrheic dermatitis, rising awareness and diagnosis, technological advancements in treatment, rising demand for natural and organic products, emerging markets, and unexplored opportunities.
Millions of people worldwide suffer from the common skin ailment known as seborrheic dermatitis. The demand for efficient therapies is driven by the growing incidence of seborrheic dermatitis, which is caused by variables like stress, pollution, hormone imbalances, and hereditary predispositions. For instance, Johnson & Johnson announced in April 2022 that the FDA has approved Tremfya (guselkumab) for the treatment of adult patients with moderate to severe seborrheic dermatitis.
By treatment, the antifungal segment accounted for the highest revenue-grossing segment in the global seborrheic dermatitis market in 2023 owing to the increased effectiveness in managing fungal infections, high prevalence of fungal-related dermatitis, and strong consumer preference for antifungal treatments. For instance, AbbVie reported in January 2022 that the FDA had approved Skyrizi (risankizumab-rzaa) for the management of adult patients with moderate to severe seborrheic dermatitis. Additionally, the anti-inflammatory segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for effective symptom relief, increasing awareness of inflammation's role in dermatitis, and advancements in anti-inflammatory formulations.
By dosage form, the shampoo segment accounted for the highest revenue-grossing segment in the global seborrheic dermatitis market in 2023 owing to the widespread use for scalp treatment, ease of application, and high consumer preference for over-the-counter solutions. For instance, Arcutis Biotherapeutics Inc. successfully acquired Ducentis BioTherapeutics Ltd. in September 2022 for $30 million, enhancing their pipeline for innovative treatments for seborrheic dermatitis. Additionally, the creams segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for targeted treatment, enhanced formulation efficacy, and greater consumer preference for topical applications.
By route of administration, the tropical segment accounted for the highest revenue-grossing segment in the global seborrheic dermatitis market in 2023 owing to the widespread use of topical treatments, ease of application, and effectiveness in managing localized symptoms. For instance, Pfizer stated in January 2023 that Phase 3 studies for a novel topical therapy for seborrheic dermatitis would begin. Additionally, the oral segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for systemic treatments, increasing cases of severe seborrheic dermatitis, and advancements in oral medication formulations.
By diagnosis, the physical examination segment accounted for the highest revenue-grossing segment in the global seborrheic dermatitis market in 2023 owing to the necessity for accurate diagnosis, frequent need for professional evaluation, and reliance on clinical assessments for effective treatment planning. For instance, Novartis released encouraging Phase 3 data in November 2022 about the use of secukinumab, an experimental therapy, to treat seborrheic dermatitis. Additionally, the biopsy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for precise diagnosis, rising awareness of complex cases, and advancements in biopsy techniques.
By end-user, the homecare segment accounted for the highest revenue-grossing segment in the global seborrheic dermatitis market in 2023 owing to the growing preference for self-management, convenience of at-home treatments, and availability of over-the-counter products. For instance, AbbVie announced in July 2023 that the FDA has approved Rinvoq (upadacitinib) for the management of adult patients with moderate to severe seborrheic dermatitis. Additionally, the specialty clinics segment is estimated to grow at the fastest CAGR during the forecast period owing to the increasing preference for expert care, advancements in specialized dermatological treatments, and rising awareness of targeted therapies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of seborrheic dermatitis, and increasing adoption of advanced treatment options. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness of dermatological conditions, expanding healthcare infrastructure, and increasing disposable income leading to greater access to treatment. For instance, GSK announced in May 2022 that the FDA had approved Eucrisa (crisaborole) to treat pediatric patients' seborrheic dermatitis.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Millions of people worldwide suffer from the common skin ailment known as seborrheic dermatitis. The demand for efficient therapies is driven by the growing incidence of seborrheic dermatitis, which is caused by variables like stress, pollution, hormone imbalances, and hereditary predispositions. For instance, Johnson & Johnson announced in April 2022 that the FDA has approved Tremfya (guselkumab) for the treatment of adult patients with moderate to severe seborrheic dermatitis.
By treatment, the antifungal segment accounted for the highest revenue-grossing segment in the global seborrheic dermatitis market in 2023 owing to the increased effectiveness in managing fungal infections, high prevalence of fungal-related dermatitis, and strong consumer preference for antifungal treatments. For instance, AbbVie reported in January 2022 that the FDA had approved Skyrizi (risankizumab-rzaa) for the management of adult patients with moderate to severe seborrheic dermatitis. Additionally, the anti-inflammatory segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for effective symptom relief, increasing awareness of inflammation's role in dermatitis, and advancements in anti-inflammatory formulations.
By dosage form, the shampoo segment accounted for the highest revenue-grossing segment in the global seborrheic dermatitis market in 2023 owing to the widespread use for scalp treatment, ease of application, and high consumer preference for over-the-counter solutions. For instance, Arcutis Biotherapeutics Inc. successfully acquired Ducentis BioTherapeutics Ltd. in September 2022 for $30 million, enhancing their pipeline for innovative treatments for seborrheic dermatitis. Additionally, the creams segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for targeted treatment, enhanced formulation efficacy, and greater consumer preference for topical applications.
By route of administration, the tropical segment accounted for the highest revenue-grossing segment in the global seborrheic dermatitis market in 2023 owing to the widespread use of topical treatments, ease of application, and effectiveness in managing localized symptoms. For instance, Pfizer stated in January 2023 that Phase 3 studies for a novel topical therapy for seborrheic dermatitis would begin. Additionally, the oral segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for systemic treatments, increasing cases of severe seborrheic dermatitis, and advancements in oral medication formulations.
By diagnosis, the physical examination segment accounted for the highest revenue-grossing segment in the global seborrheic dermatitis market in 2023 owing to the necessity for accurate diagnosis, frequent need for professional evaluation, and reliance on clinical assessments for effective treatment planning. For instance, Novartis released encouraging Phase 3 data in November 2022 about the use of secukinumab, an experimental therapy, to treat seborrheic dermatitis. Additionally, the biopsy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for precise diagnosis, rising awareness of complex cases, and advancements in biopsy techniques.
By end-user, the homecare segment accounted for the highest revenue-grossing segment in the global seborrheic dermatitis market in 2023 owing to the growing preference for self-management, convenience of at-home treatments, and availability of over-the-counter products. For instance, AbbVie announced in July 2023 that the FDA has approved Rinvoq (upadacitinib) for the management of adult patients with moderate to severe seborrheic dermatitis. Additionally, the specialty clinics segment is estimated to grow at the fastest CAGR during the forecast period owing to the increasing preference for expert care, advancements in specialized dermatological treatments, and rising awareness of targeted therapies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of seborrheic dermatitis, and increasing adoption of advanced treatment options. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness of dermatological conditions, expanding healthcare infrastructure, and increasing disposable income leading to greater access to treatment. For instance, GSK announced in May 2022 that the FDA had approved Eucrisa (crisaborole) to treat pediatric patients' seborrheic dermatitis.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Treatment, Dosage Form, Route of Administration, Diagnosis, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Seborrheic Dermatitis Market Report 2023 - 2034
Seborrheic Dermatitis Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Anti-inflammatory
- Antifungal
- Corticosteroid Lotions
- Sulphur Products
- Others
Seborrheic Dermatitis Market Analysis & Forecast by Dosage Form 2023 - 2034 (Revenue USD Bn)
- Creams
- Shampoos
- Ointments
- Gels
- Others
Seborrheic Dermatitis Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Oral
- Topical
- Parenteral
- Others
Seborrheic Dermatitis Market Analysis & Forecast by Diagnosis 2023 - 2034 (Revenue USD Bn)
- Physical Examination
- Biopsy
- Others
Seborrheic Dermatitis Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Specialty Clinics
- Homecare
- Others
Seborrheic Dermatitis Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Seborrheic Dermatitis Market: Treatment Estimates & Trend Analysis
8. Seborrheic Dermatitis Market: Dosage Form Estimates & Trend Analysis
9. Seborrheic Dermatitis Market: Route of Administration Estimates & Trend Analysis
10. Seborrheic Dermatitis Market: Diagnosis Estimates & Trend Analysis
11. Seborrheic Dermatitis Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Seborrheic Dermatitis Market
14. Europe Global Seborrheic Dermatitis Market
15. Asia Pacific Global Seborrheic Dermatitis Market
16. Latin America Global Seborrheic Dermatitis Market
17. MEA Global Seborrheic Dermatitis Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Pfizer Inc.
- Novartis International AG
- Galderma S.A.
- GlaxoSmithKline plc
- AbbVie Inc.
- Bayer AG
- L'Oréal S.A.
- Sanofi S.A.
- Merck & Co. Inc.
- Leo Pharma A/S
- Bausch Health Companies Inc.
- Valeant Pharmaceuticals International Inc.
- Perrigo Company plc
- Cipla Limited.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.68 Billion |
| Forecasted Market Value ( USD | $ 8.48 Billion |
| Compound Annual Growth Rate | 11.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
